Drug's - Delivery and dosage

Clinical Target Product Profiling is the method used for relative comparison of the investigational drug with the current standard and emerging therapies on key evaluation parameters of efficacy, safety, delivery and dosing for the targeted indication. A weighted average score relative to the SOC helps position the investigational drug and serves as the basis for estimating the patient share and price.

Drug has promising revenue potential but what about expenses?
Estimating the revenue potential of the drug is only half the story. It is equally important to accurately estimate the developmental expenses.

Clinical trial expenses constitute the majority (~75-80%) of the total developmental expenses. Clinical Development Plan (CDP) with details of planned trials needs to be carved out to estimate clinical trial expenses. The clinical trial expenses are then allocated across the ‘initialization’, ‘study’ and ‘close out’ phases of the trial to accurately reflect the spends.

Non-clinical studies should be carefully planned in accordance with the regulatory requirement of the intended country. Cost estimations are based on the number and type of studies that will be needed.

Other expenses such as manufacturing, regulatory, selling, general and administrative and pharmacovigilance expenses also need to be estimated accurately for the investigational drug.

Cheap natural gas

Petrochemical companies are making multibillion-dollar bets to profit from the abundant cheap natural gas pouring out of shale-rock formations across the U.S. Making sure those plans pay off.

Natural-gas prices have plummeted in recent years as a new wave of supply has been unlocked from Texas to Pennsylvania through technological advances, including horizontal drilling and hydraulic fracturing. The low prices have been tough on some oil and gas companies' bottom lines. But the trend has given chemical and plastics producers a reason to expand in the U.S., creating jobs and reviving a sector of the economy that many people had written off.

The manufacturing renaissance sweeping across the U.S. today is a shift from the turn of this century, when it seemed unlikely that new petrochemical plants would be built in places such as the coastal region near the Gulf of Mexico.

The assumption was that new petrochemical plants and associated investments in plastics, rubber resins and metals manufacturing would be focused in Asia and countries rich in natural gas, such as Iran. 

 

The resurrection of U.S. manufacturing in the service of developing the chemical sector and pumping more oil and gas—including building machinery and fabricating steel and iron—is breathing new life into major metropolitan areas.

From 2010 to 2012, energy-intensive manufacturing sectors added more than 196,000 U.S. jobs and increased real sales by $124 billion in the nation's metro areas, according to the report.